| Latest | F'cast | |
|---|---|---|
| Div Yield | 1.9% | 0.0% |
| Div Cover | 2.6 | 2.8 |
| Op Mrgn | 18.5% | 30.8% |
| ROCE | 60.7% |
| Latest | F'cast | |
|---|---|---|
| P/E | 19.9 | 18.3 |
| PEG | 1.5 | 1.7 |
| Pr/Revenue | 4.7 | 3.3 |
| Pr/Book | 6.2 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 18.0% | -18.2% |
| PBT | 26.0% | 56.5% |
| EPS | 13.1% | 10.6% |
| DPS | 6.9% | -40.3% |
| Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-20 | 26,617.00 | 3,916.00 | 244.00¢ | 39.5 | 0.3 | +137% | 280.00¢ | 2.9% |
| 31-Dec-21 | 37,417.00 | (265.00) | 8.00¢ | 1,426.5 | n/a | -97% | 287.00¢ | 2.5% |
| 31-Dec-22 | 44,351.00 | 2,501.00 | 212.00¢ | 69.6 | 0.0 | +2,550% | 290.00¢ | 2.0% |
| 31-Dec-23 | 45,811.00 | 6,899.00 | 726.00¢ | 19.2 | 0.1 | +242% | 290.00¢ | 2.1% |
| 31-Dec-24 | 54,073.00 | 8,691.00 | 821.00¢ | 16.8 | 1.3 | +13% | 310.00¢ | 2.3% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-25 | 58,156.23 | 17,885.97 | 681.47p | 18.3 | 1.7 | +11% | 243.19p | 0.0% |
| 31-Dec-26 | 61,696.17 | 20,451.78 | 772.27p | 16.1 | 1.2 | +13% | 256.05p | 0.0% |
| 31-Dec-27 | 65,231.66 | 22,382.40 | 859.20p | 14.5 | 1.3 | +11% | 266.67p | 0.0% |
Copyright © 2025 FactSet Research Systems Inc. All rights reserved.
| Director Declaration | 28-Oct-2025 | 07:05 | RNS |
| Koselugo (selumetinib) approved in the EU | 28-Oct-2025 | 07:00 | RNS |
| Tezspire Approved in EU for CRSwNP | 22-Oct-2025 | 07:00 | RNS |
| AstraZeneca's Koselugo receives EU approval | 28-Oct-2025 | ShareCast |
| Astrazeneca's Tezspire secures EU approval | 22-Oct-2025 | ShareCast |
| AstraZeneca lupus treatment gets EU approval | 20-Oct-2025 | ShareCast |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 12,470.00p |
| Change Today | -76.00p |
| % Change | -0.61 % |
| 52 Week High | 12,940.00 |
| 52 Week Low | 9,667.00 |
| Volume | 1,076,537 |
| Shares Issued | 1,550.70m |
| Market Cap | £193,372m |
| Beta | 1.32 |
| RiskGrade | 123 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 9 |
| Buy | 13 |
| Neutral | 4 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 27 |

| Latest | Previous | |
|---|---|---|
| 1st Interim | 2nd Interim | |
| Ex-Div | 07-Aug-25 | 20-Feb-25 |
| Paid | 08-Sep-25 | 24-Mar-25 |
| Amount | 103.00¢ | 210.00¢ |
| Time | Volume / Share Price |
| 14:42 | 0 @ 12,524.00p |
| 14:40 | 0 @ 12,522.00p |
| 14:41 | 2 @ 12,518.00p |
| 16:49 | 18 @ 12,470.00p |
| 16:48 | 2 @ 12,470.00p |
You are here: research